Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burns, Mary Ann
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD	Active, not recruiting	4	123	US	Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)	Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials	Attention Deficit/Hyperactivity Disorder	07/25	07/25
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer	Withdrawn	2	200	US	Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane	Veru Inc.	Metastatic Breast Cancer	03/24	05/24
Sonnier, Scott
NCT05079360: Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer	Withdrawn	2	200	US	Sabizabulin, Veru-111, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator, exemestane	Veru Inc.	Metastatic Breast Cancer	03/24	05/24